Our Comprehensive CDMO Services
| Phase | Solution | Capability | Infrastructure |
|---|---|---|---|
| Pre-clinical |
|
|
|
| Phases 1–3 (Clinical Development) |
|
|
|
| Commercial | Commercial manufacturing |
|
|
Ready to discuss your project?
Our Core Capabilities
Small Molecules
Robust development and manufacturing for complex and high value APIs across clinical and commercial stages.
Peptides (SPPS / LPPS / Hybrid)
Integrated peptide solutions leveraging solid phase, liquid phase, and hybrid technologies for optimal scalability and cost efficiency.
Custom Synthesis
Non infringing routes, difficult chemistries, controlled impurities, and reproducible processes tailored to your molecule.
Why European & UK Companies Choose Neuland?
Relevant EU & UK Regulatory Strength
- USFDA & EU-GMP compliant manufacturing facilities.
- Successful inspections by USFDA, EMA, PMDA and other global regulators
Proven partners for European innovators
- Supported biotech and pharma clients across Europe over decade including progressing molecules from Phase I through NDA and commercial supply, often acting as first supplier on regulatory filings
- Complex chemistry strength - proven handling of challenging syntheses, impurities and scale up risk.
Early-stage development to Commercial Manufacturing CDMO
- Scalable process development from route scouting to feasibility
- QbD and DoE embedded across development stages
- Early design to minimise scale up and validation risk
Evaluate your molecule with us
Confidential technical discussion • No obligation • NDA available on request
Case Studies: Solving complex development & scale‑Up challenges
Phase III to Commercial CNS API
Converting a High‑Risk CNS API into a Scalable Asset
Read case study
